The Secret Sauce To BenevolentAI’s Ongoing Success
In a crowded AI-driven drug development sector, BenevolentAI stands out with its broad pipeline of drug candidates, deep pockets, and a growing partnership with AstraZeneca. Ivan Griffin, company co-founder and chief operating officer spoke with In Vivo about the formula behind the company’s successes.
You may also be interested in...
The company's biopharma R&D chief tells Scrip about trying to unlock the potential of the the vast amount of data produced to improve the understanding of complex disease biology and identify new targets to treat debilitating diseases.
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.